Eric Whitman, MD

Dr Whitman introduces cosibelimab, the third checkpoint inhibitor approved in advanced cutaneous squamous cell carcinoma, and the faculty examine what distinguishes it mechanistically from cemiplimab and pembrolizumab.

The faculty examine KEYNOTE-630, the adjuvant trial of pembrolizumab in cutaneous squamous cell carcinoma, and why it produced a different result than C-POST.

Dr Whitman and Dr In discuss the FDA approval of adjuvant cemiplimab for patients with high-risk cutaneous squamous cell carcinoma who have completed surgery and adjuvant radiation yet remain at elevated risk for recurrence.

Eric Whitman, MD, of Atlantic Health, and Gino K. In, MD, MPH, of USC Norris Comprehensive Cancer Center, open this OncLive My Treatment Approach program on matching immunotherapy to the patient in advanced cutaneous squamous cell carcinoma.

Drs Whitman and Patel discuss the evolving treatment paradigm for patients with CSCC, emphasizing the role of neoadjuvant and adjuvant immunotherapies.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses ways to expand the benefit of immunotherapy in non-immunogenic solid tumors.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses eliminating financial toxicity in oncology.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses improving precision medicine in oncology.

Eric Whitman, MD, medical director of Atlantic Health System Cancer Care, Atlantic Health System, discusses the partnership between Atlantic Health System, Translational Genomics Research Institute (TGen), and Origin Commercial Ventures.

Eric Whitman, MD, surgeon, Atlantic Health System, discusses the role of pembrolizumab (Keytruda) in the treatment of patients with melanoma.